Tessera Therapeutics, Inc.
Tessera Therapeutics is pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Their mission is to cure disease by writing in the code of life, expanding possibilities in genetic medicine through versatile technologies including Gene Writing™, delivery systems, and focus areas targeting major unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Gene writing technology platform
A platform combining RNA- and DNA-based gene writers to enable precise and durable genomic alterations (single-base edits, exon replacement, whole-gene insertion) without introducing double-strand breaks.
Lipid nanoparticle (LNP) delivery platform
Non-viral LNP formulation and delivery platform for RNA payloads, engineered for safety, scalability, re-dosability, transient expression of editing machinery, and directed tissue targeting beyond the liver.
Gene writing technology platform
A platform combining RNA- and DNA-based gene writers to enable precise and durable genomic alterations (single-base edits, exon replacement, whole-gene insertion) without introducing double-strand breaks.
Lipid nanoparticle (LNP) delivery platform
Non-viral LNP formulation and delivery platform for RNA payloads, engineered for safety, scalability, re-dosability, transient expression of editing machinery, and directed tissue targeting beyond the liver.
Expertise Areas
- Gene writing and genome engineering
- Non-viral LNP delivery development and tissue targeting
- Mobile genetic element discovery and engineering
- Clinical development and translational sciences for gene therapies
Key Technologies
- Target-primed reverse transcription (TPRT)
- RNA-based gene writers (template RNA + protein)
- DNA-based gene writers for large-sequence integration
- Lipid nanoparticle (LNP) delivery systems